Johns Hopkins University

David Lee Thomas

Stuart Campbell Ray

Justin R Bailey

Robert Siliciano

Joel Blankson

Ramy El-Diwany

Michel Anand Chattergoon

Ashwin Balagopal

Andrew L Cox

Three proteins, BCL-G (BCL2L14), CMPK2, and LAMP3, were discovered to independently restrict HIV-1 replication both in-vivo and in-vitro. Methods are described wherein subjects are given an effective amount of a pharmaceutical composition comprising a protein selected from the group consisting of BCL-G, CMPK2, LAMP3, functional parts thereof, recombinant proteins thereof, and combinations thereof, for the purpose of treating or preventing HIV.

Antiviral proteins and their uses in therapeutic methods

The invention provides consensus sequences for hepatitis C virus 1a and 1b. Also provided are non-synonymous changes for each residue of the consensus sequences. These sequences are useful as compositions or vaccines for prophylactic use or treating HCV-infected individuals. Also provided are methods for lessening the chances for a HCV-infected individual to enter a chronic phase of infection and methods of diagnosing an individual with HCV 1a or HCV 1b infection.

Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants

Growing community of inventors

Lutherville, MD, United States of America

David Lee Thomas